Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

Blood blood.2024025624.

https://doi.org/10.1182/blood.2024025624

Published: 2024

Includes: Supplemental data

Journal Articles

Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression

Jon Thorir Oskarsson, Sæmundur Rögnvaldsson, Sigrun Thorsteinsdottir, Andri Olafsson, Elias Eythorsson, Asbjorn Jonsson, Brynjar Vidarsson, Pall T. Onundarson, Bjarni Agnarsson, Margret Sigurdardottir, Ingunn Thorsteinsdottir, Isleifur Olafsson, Stephen J. Harding, Brian G.M. Durie, Thorvardur Jon Love, Sigurdur Y Kristinsson

Blood (2024) 144 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2024-200422

Published: 2024

Journal Articles

The Early Benefits and Psychological Effects of Screening for Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

Blood (2023) 142 (Supplement 1): 214.

https://doi.org/10.1182/blood-2023-186397

Published: 2023

Journal Articles

Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombotic Events: Results from Istopmm, a Population-Based Screening Study in Iceland

Blood (2023) 142 (Supplement 1): 216.

https://doi.org/10.1182/blood-2023-186098

Published: 2023

Journal Articles

Sars-Cov-2 Infection Does Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Blood (2023) 142 (Supplement 1): 4766.

https://doi.org/10.1182/blood-2023-173078

Published: 2023

Journal Articles

Predicting an Underlying Clonal Plasma Cell Population in Light-Chain Monoclonal Gammopathy of Undetermined Significance Using Free Light-Chain Ratio

Blood (2023) 142 (Supplement 1): 530.

https://doi.org/10.1182/blood-2023-182661

Published: 2023

Journal Articles

Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

Blood (2023) 142 (Supplement 1): 535.

https://doi.org/10.1182/blood-2023-188547

Published: 2023

Journal Articles

Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study

Blood (2023) 142 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2023-188469

Published: 2023

Journal Articles

Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study

Alma R. Oskarsdottir, Brynja R. Gudmundsdottir, Hulda M. Jensdottir, Bjorn Flygenring, Ragnar Palsson, Pall T. Onundarson

Blood (2021) 137 (20): 2745–2755.

https://doi.org/10.1182/blood.2020008698

Published: 2021

Includes: Supplemental data

Journal Articles

Replacing PT-INR Monitoring of Warfarin with Fiix-NR in Clinical Practice Reduces Thromboembolism without Increasing Bleeding Despite Reduced Number of Dose Adjustments

Alma R. Oskarsdottir, MD, Brynja R. Gudmundsdottir, MS, Pall T. Onundarson, MD

Blood (2018) 132 (Supplement 1): 1239.

https://doi.org/10.1182/blood-2018-99-116731

Published: 2018

Journal Articles

Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial

Alma R. Oskarsdottir, BS, Brynja R. Gudmundsdottir, MS, Olafur S. Indridason, MD MPH, Hulda M. Jensdottir, BS, David O. Arnar, MD PhD, Einar S. Bjornsson, MD PhD, Magnus K. Magnusson, MD, Sigrun H. Lund, PhD, Brynjar Vidarsson, MD, Charles W. Francis, MD, Pall T. Onundarson, MD

Blood (2015) 126 (23): 1129.

https://doi.org/10.1182/blood.V126.23.1129.1129

Published: 2015

Journal Articles

Gender Differences during Long-Term Warfarin Anticoagulation in Patients with Atrial Fibrillation Monitored with Fiix-Prothrombin Time or Prothrombin Time. the Fiix Trial

Hulda M. Jensdottir, BS, Brynjar Vidarsson, MD, Brynja R. Gudmundsdottir, MS, Alma R. Oskarsdottir, BS, Olafur S. Indridason, MD MPH, David O. Arnar, MD PhD, Einar S. Bjornsson, MD PhD, Magnus K. Magnusson, MD, Sigrun H. Lund, PhD, Charles W. Francis, MD, Pall T. Onundarson, MD

Blood (2015) 126 (23): 1134.

https://doi.org/10.1182/blood.V126.23.1134.1134

Published: 2015

Journal Articles

Monitoring Warfarin with the Fiix-Prothrombin Time Improves Anticoagulation Stability and Long-Term Clinical Outcome. the Fiix-Trial

Pall T. Onundarson, MD, Charles W. Francis, MD, Einar S. Bjornsson, MDPhD, Magnus K. Magnusson, MD, David O. Arnar, MD, Olafur S. Indridason, MD, Sigrun Helga Lund, PhD, Sigurdur J. Juliusson, BS, Hulda M. Jensdottir, Brynja R. Gudmundsdottir, MS

Blood (2014) 124 (21): 347.

https://doi.org/10.1182/blood.V124.21.347.347

Published: 2014

Journal Articles

INR and Vitamin K Dependent Coagulation Factor Fluctuation during Warfarin Initiation and Stable Therapy in Patients Dosed with the Fiix-Prothrombin Time or the Quick Prothrombin Time. the Fiix Trial

Brynja R. Gudmundsdottir, MS, Petur I. Jonsson, Pall T. Onundarson, MD

Blood (2014) 124 (21): 4278.

https://doi.org/10.1182/blood.V124.21.4278.4278

Published: 2014

Journal Articles

Critical Role of Factors II and X During Coumarin Anticoagulation and Their Combined Measurement with a New Prothrombin Time Variant (Fiix-PT),

Pall T. Onundarson, MD, Brynja R. Gudmundsdottir, MS, Charles W. Francis, MD

Blood (2011) 118 (21): 3354.

https://doi.org/10.1182/blood.V118.21.3354.3354

Published: 2011

Journal Articles

Activated Recombinant Factor VIIa for Intractable Extra-Cranial Hemorrhage in 55 Consecutive Patients

Brynjar Vidarsson, MD, Robert Palmason, MD, Tomas Gudbjartsson, MD PhD, Pall T. Onundarson, MD

Blood (2011) 118 (21): 1264.

https://doi.org/10.1182/blood.V118.21.1264.1264

Published: 2011

Journal Articles

Coagulation Induced by Dilute Tissue Factor Depends More Critically on Factor II and X Concentration Than on FVII or FIX

Brynja R. Gudmundsdottir, MSc, Alexia M Bjornsdottir, B.Sc., Pall T. Onundarson, MD

Blood (2008) 112 (11): 4084.

https://doi.org/10.1182/blood.V112.11.4084.4084

Published: 2008

Journal Articles

Recombinant Factor VIIa Combined with Fibrinogen Corrects the Coagulopathy Associated with Cardiopulmonary Bypass Surgery Ex Vivo

Pall T. Onundarson, M.D., Hanna S. Asvaldsdottir, M.Sc., Brynja R. Gudmundsdottir, M.Sc., Benny Sorensen, M.D., Ph.D.

Blood (2008) 112 (11): 4097.

https://doi.org/10.1182/blood.V112.11.4097.4097

Published: 2008

Journal Articles

Economy Class Syndrome: A “Pilot” Study.

Sigurdur Y. Kristinsson, MD, Brynjar Vidarsson, MD, Thorvardur J. Love, MD, Vilhjalmur Rafnsson, MD, Jon Hrafnkelsson, MD, Pall T. Onundarson, MD

Blood (2005) 106 (11): 4130.

https://doi.org/10.1182/blood.V106.11.4130.4130

Published: 2005

NARROW

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression

The Early Benefits and Psychological Effects of Screening for Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombotic Events: Results from Istopmm, a Population-Based Screening Study in Iceland

Sars-Cov-2 Infection Does Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study

Predicting an Underlying Clonal Plasma Cell Population in Light-Chain Monoclonal Gammopathy of Undetermined Significance Using Free Light-Chain Ratio

Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study

Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study

Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study

Replacing PT-INR Monitoring of Warfarin with Fiix-NR in Clinical Practice Reduces Thromboembolism without Increasing Bleeding Despite Reduced Number of Dose Adjustments

Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial

Gender Differences during Long-Term Warfarin Anticoagulation in Patients with Atrial Fibrillation Monitored with Fiix-Prothrombin Time or Prothrombin Time. the Fiix Trial

Monitoring Warfarin with the Fiix-Prothrombin Time Improves Anticoagulation Stability and Long-Term Clinical Outcome. the Fiix-Trial

INR and Vitamin K Dependent Coagulation Factor Fluctuation during Warfarin Initiation and Stable Therapy in Patients Dosed with the Fiix-Prothrombin Time or the Quick Prothrombin Time. the Fiix Trial

Critical Role of Factors II and X During Coumarin Anticoagulation and Their Combined Measurement with a New Prothrombin Time Variant (Fiix-PT),

Activated Recombinant Factor VIIa for Intractable Extra-Cranial Hemorrhage in 55 Consecutive Patients

Coagulation Induced by Dilute Tissue Factor Depends More Critically on Factor II and X Concentration Than on FVII or FIX

Recombinant Factor VIIa Combined with Fibrinogen Corrects the Coagulopathy Associated with Cardiopulmonary Bypass Surgery Ex Vivo

Economy Class Syndrome: A “Pilot” Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only